Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11323975 | 0.81 | KDM4E (0.61) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL19555 | 0.77 | OGT (1.00) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL29475399 | 0.77 | OGT (1.00) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL3927631 | 0.77 | OGT (1.00) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL9110846 | 0.77 | OGT (1.00) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL28920994 | 0.76 | OGT (0.95) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL28598217 | 0.76 | OGT (0.95) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| Benzoxazolinone SCHEMBL3650873 | 0.76 | OGT (0.95) | OGTKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10904965 | 0.75 | PARP1 (0.65) | KDM4EALDH1A1PARP1MEN1TNKS | |
| Benzoxazolinone SCHEMBL385987 | 0.74 | OGT (0.81) | OGTKDM4EGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0028392-B1 | PROCESS FOR THE PREPARATION OF 2,3-DIOXO-1,4-BENZOXAZINE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | claimed |
| US-4297491-A | Preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | claimed |
| WO-2023216753-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 上海赛默罗生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-110950856-B | 8- (benzofuran-5-yl) benzoxazine diones and their use as anti-cancer agents | 湖南大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-110950856-A | 8- (benzofuran-5-yl) benzoxazine diones and their use as anti-cancer agents | 湖南大学 | 2020-04-03 | — | — | CN | disclosed |
| EP-2947073-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2019-04-03 | — | — | EP | disclosed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| EP-0142361-A2 | N-substituted-5-phenyl-4,1-benzoxazepin-2(3H)-ones having therapeutic utility | THE UPJOHN COMPANY (US) | 1985-05-22 | — | — | EP | disclosed |
| EP-0028392-B1 | PROCESS FOR THE PREPARATION OF 2,3-DIOXO-1,4-BENZOXAZINE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0028392-B1 | PROCESS FOR THE PREPARATION OF 2,3-DIOXO-1,4-BENZOXAZINE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4307091-A | Process for treatment of allergic conditions with benzoxazinediones | USV PHARMACEUTICAL CORPORATION (US) | 1981-12-22 | — | — | US | disclosed |
| US-4297491-A | Preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | disclosed |
| US-4297491-A | Preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | disclosed |
| US-4297491-A | Preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | disclosed |
| EP-0028392-A1 | Process for the preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF Aktiengesellschaft (DE) | 1981-05-13 | — | — | EP | disclosed |
| EP-0028392-A1 | Process for the preparation of 2,3-dioxo-1,4-benzoxazine derivatives | BASF Aktiengesellschaft (DE) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | OGT 3810/4885KDM4E 209/4885GRIN2D 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.